Pharmafile Logo

EGFR inhibitor

- PMLiVE

Regeneron’s Libtayo approved as flexible dosing schedule in EU

The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

- PMLiVE

Roche’s Gazyva/Gazyvaro approved by FDA for primary membranous nephropathy

This rare, chronic autoimmune disease can cause kidney failure if left untreated

- PMLiVE

Nuformix proposes acquisition of Biovara

The companies focus on fibrosis and oncology, and novel treatments for respiratory conditions, respectively

- PMLiVE

Novartis presents positive results from two phase 3 trials for relapsing MS

Remibrutinib reduced relapse rates and improved disease progression rates

- PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

Biogen announces phase 2 data for cutaneous lupus erythematosus

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

People smiling in meeting

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

HCP engaging with elderly patient

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links